The DOI matches its Crossref record; 249 of the 249 references it cites were found in a registry or an index.
Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease
Open accessAbstract
Chronic kidney disease (CKD) is a global health problem with rising incidence and prevalence. Among several pathogenetic mechanisms responsible for disease progression, lipid accumulation in the kidney parenchyma might drive inflammation and fibrosis, as has been described in fatty liver diseases. Lipids and their metabolites have several important structural and functional roles, as they are constituents of cell and organelle membranes, serve as signalling molecules and are used for energy production. However, although lipids can be stored in lipid droplets to maintain lipid homeostasis, lipid accumulation can become pathogenic. Understanding the mechanisms linking kidney parenchymal lipid accumulation to CKD of metabolic or non-metabolic origin is challenging, owing to the tremendous variety of lipid species and their functional diversity across different parenchymal cells. Nonetheless, multiple research reports have begun to emphasize the effect of dysregulated kidney lipid metabolism in CKD progression. For example, altered cholesterol and fatty acid metabolism contribute to glomerular and tubular cell injury. Newly developed lipid-targeting agents are being tested in clinical trials in CKD, raising expectations for further therapeutic development in this field. Chronic kidney disease is characterized by dyslipidaemia and lipid accumulation in the kidney. In this Review, the authors examine the evidence that links alterations in lipid metabolism to kidney injury and progression of kidney disease, and explore potential lipid-targeted therapeutic approaches. Lipids and lipid-related enzymes have a major role in modulating the function of glomerular and tubular cells, and can drive chronic kidney disease (CKD) irrespective of circulating lipid levels. The mechanisms that initiate the accumulation of kidney lipids might differ between CKD of different aetiologies. Thus, the accumulation of kidney lipids in diabetic kidney disease is driven by increased glucose and fatty acids levels owing to insulin resistance, whereas in glomerulonephritis, inflammation can disrupt normal kidney lipid metabolism. Several lipid species, such as cholesterol, triglycerides, fatty acids and phospholipids, are dysregulated in podocytes, endothelial and tubular cells, and contribute to CKD progression. Accumulation of kidney parenchymal cholesterol occurs in association with impaired reverse cholesterol transport in diseases of both metabolic and non-metabolic origin, and contributes to CKD progression. Accumulation of fatty acids triggers mitochondrial and kidney cell damage by promoting inflammation, including cellular sterile inflammation, via innate immune system activation and fibrosis; lipophagy has a protective effect. Lipids and lipid-related enzymes have a major role in modulating the function of glomerular and tubular cells, and can drive chronic kidney disease (CKD) irrespective of circulating lipid levels. The mechanisms that initiate the accumulation of kidney lipids might differ between CKD of different aetiologies. Thus, the accumulation of kidney lipids in diabetic kidney disease is driven by increased glucose and fatty acids levels owing to insulin resistance, whereas in glomerulonephritis, inflammation can disrupt normal kidney lipid metabolism. Several lipid species, such as cholesterol, triglycerides, fatty acids and phospholipids, are dysregulated in podocytes, endothelial and tubular cells, and contribute to CKD progression. Accumulation of kidney parenchymal cholesterol occurs in association with impaired reverse cholesterol transport in diseases of both metabolic and non-metabolic origin, and contributes to CKD progression. Accumulation of fatty acids triggers mitochondrial and kidney cell damage by promoting inflammation, including cellular sterile inflammation, via innate immune system activation and fibrosis; lipophagy has a protective effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Oxyl radicals, redox-sensitive signalling cascades and antioxidants
Genestra, M. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.04.009 · Cited by 4,930
Webster, A. C., Nagler, E. V., Morton, R. L., & Masson, P. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32064-5 · Cited by 3,842
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Empagliflozin in Patients with Chronic Kidney Disease
The EMPA-KIDNEY Collaborative Group (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2204233 · Cited by 2,754
Dynamics and functions of lipid droplets
Olzmann, J. A., & Carvalho, P. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0085-z · Cited by 2,740
Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., Wanner, C., Krane, V., Cass, A., Craig, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60739-3 · Cited by 2,479
Cited by
Chen, Y.-R., Lin, S.-B., Lv, J.-Y., Wu, Y., & Feng, W.-R. (2024) · Environmental Pollution · doi:10.1016/j.envpol.2024.124865 · Cited by 25
Tramontano, D., D'Erasmo, L., Larouche, M., Brisson, D., Lauzière, A., Di Costanzo, A., Bini, S., Minicocci, I., Covino, S., Baratta, F., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119146 · Cited by 23
Metadata
- Authors
- Mitrofanova, A., Merscher, S., & Fornoni, A.
- Venue
- Nature Reviews Nephrology
- Published
- 2023-07-27
- Volume
- 19
- Issue
- 10
- Pages
- 629-645
- ISSN
- 1745-8323 (ISSN-L)
- 1759-5061
- 1759-507X
- OpenAlex
- W4385331218
- Cited by
- 356
- References
- 249
- FWCI
- 20.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease. https://app.cochat.ai/papers/10.1038/s41581-023-00741-w
- The paper
- Mitrofanova, A., Merscher, S., & Fornoni, A. (2023). Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease. Nature Reviews Nephrology. https://doi.org/10.1038/s41581-023-00741-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.